Ge Healthcare Technologies Inc. GEHC

Revenue Intelligence Report • 16 quarters of SEC filing data • Updated 2026-03-06

Ge Healthcare Technologies Inc. demonstrates a strong revenue generation model, with $1 of SG&A spending yielding an impressive $2.24 in long-run revenue, while R&D spending has a negative impact on revenue. The latest quarterly revenue of $5,698 million reflects a robust performance, although the holdout test revealed a 9.9% prediction error. The company is forecasting a remarkable $882 billion in revenue for the fiscal year, representing a staggering 4,175.6% year-over-year growth. This outlook, combined with a low MAPE of 1.9%, suggests a promising trajectory for financial investors.

Next FY Revenue

$881.84B

+4175.6% YoY

R&D Multiplier

$-1.88 per $1

SG&A Multiplier

$2.24 per $1

Model Accuracy

1.9% MAPE

Holdout validation: The model predicted $5B vs the actual $6B — an error of 9.9%.

⚠ Model limitation: This company shows negative spending multipliers, meaning increases in spending have not directly translated into revenue growth. This typically occurs with commodity-driven companies or hypergrowth companies.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$5B	$6B	$5B – $5B	-3.5%	✗ Outside range
Q2 2026	$9B		$9B – $9B	+90.4%
Q3 2026	$27B		$27B – $28B	+445.5%
Q4 2026	$131B		$130B – $131B	+2445.7%
Q1 2027	$714B		$714B – $715B	+12439.5%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch